CA-USERTESTING
26.7.2022 09:02:12 CEST | Business Wire | Press release
UserTesting (NYSE: USER), a leader in video-based human insight , today announced that UserTesting CEO Andy MacMillan will be joining host Nick Murray, Co-Director Startup Grind Scotland and Strategic Partnerships Manager, Metanomic, for a discussion focused on topics that include empathy in leadership, and what makes Edinburgh an ideal location as a European headquarters for technology companies. This event is taking place on Thursday, August 4, at UserTesting’s European headquarters in Edinburgh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005085/en/
Attendees also can hear what Scotland can learn from Silicon Valley’s mindset, the value of customer insights in helping to drive business decisions during challenging economic periods, and lessons learned from rapidly growing a SaaS company through an IPO.
Discussion Details:
- Date: Thursday, August 4, 2022
- Time: 6:00 p.m. to 9:00 p.m., BST
- Location: UserTesting EMEA Headquarters, 2nd Floor, 7 Exchange Crescent, Edinburgh, EH3 8AN
- Cost: 6 GBP public, Free for UserTesting team members (prior registration required)
-
Speakers:
- Andy MacMillan, CEO of UserTesting
- Nick Murray, Host and Co-Director Startup Grind Scotland
"Community gatherings with globally-proven industry experts are critical to developing Scotland's entrepreneurial ecosystem," said Nick Murray, Co-Director of Startup Grind Scotland. "Our first interview with Andy in Silicon Valley this April was a significant mindset shift for the 20 Scottish founders we took to the entrepreneurship mecca. With the Scottish Government announcing Scotland's Tech Scaler Hubs this month, now is the perfect time to look internationally to find best practices and learn from those who have been there before. This interview will broaden the horizons of what's possible for Scottish businesses through the eyes of someone who has had incredible success in scaling a SAAS business to a global entity."
“Selecting Edinburgh was the right choice for UserTesting’s European headquarters, and we are excited to be a part of this event, highlighting the value we have found in establishing offices here,” said Andy MacMillan, CEO of UserTesting. “UserTesting is proud to support Edinburgh’s, and Scotland’s, growing technology scene. There are great opportunities for companies in Scotland, due to the local education system, partnership opportunities with local government agencies, and the local talent, which is what global technology companies are looking for today.”
About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has approximately 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com
.
About Startup Grind Scotland
Startup Grind is the world's largest community of startups, founders, innovators, and creators based in 125+ countries with 600 chapters worldwide. Startup Grind Scotland is committed to supporting Scotland's vibrant entrepreneurial community, hosting fireside chats and panel conversations with some of Scotland's most influential and exciting business leaders. Past speakers include Mark Logan (Scotland's Chief Entrepreneur and ex-Skyscanner COO), Darina Garland (co-founder, Ooni) and Evelyn McDonald (CEO, Scottish EDGE).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005085/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom